EUCTR2014-000137-22-DE进行中（未招募）1 期
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection - MK-5172 in Combination with MK-8742 in Treatment-Naïve Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •You are greater than or equal to 18 years of age
- •You have chronic HCV GT1, GT4, GT5, GT6
- •You have had a liver biopsy, Fibroscan or Fibrotest to check for cirrhosis or no cirrhosis
- •You are treatment naïve to all anti-HCV treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 320
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •You have signs of decompensated liver disease
- •You are coninfected with Hepatitis B
- •You have signs of hepatocellular carcinoma or history of malignancy
- •You are taking or plan to take any medication not allowed for this study
- •You have a history of, or signs of, chronic hepatitis not caused by hepatitis C virus
- •You have an exclusionary laboratory value
研究者
相似试验
进行中（未招募）
1 期
Sitagliptin with atorvastatin in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin monotherapy.Type 2 diabetes mellitusMedDRA version: 14.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-003600-20-BGMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.825
进行中（未招募）
不适用
MK-5172 in Combination with MK-8742 with and without Ribavirin (RBV) in HCV patients who failed Prior pegylated interferon (peg-IFN) and RBV treatmentHepatitis CEUCTR2014-000824-12-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc400
进行中（未招募）
1 期
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, and GT6 Infection who are on Opiate Substitution Therapy.MedDRA version: 20.0Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848Hepatitis CEUCTR2014-000343-32-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,301
进行中（未招募）
不适用
Sitagliptin with atorvastatin in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin monotherapy.Type 2 diabetes mellitusMedDRA version: 15.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-003600-20-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.825
进行中（未招募）
不适用
MK-5172 in Combination with MK-8742 with and without Ribavirin (RBV) in HCV patients who failed Prior pegylated interferon (peg-IFN) and RBV treatmentMedDRA version: 17.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsHepatitis CEUCTR2014-000824-12-NLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc400